Author Details
₹165
(Inclusive of all Taxes)
₹24.8 Cashback (15%)
coupon
Available Offers
APLICICISave 19% on medicine orders above Rs. 1999 with ICICI credit Card
ONECARD5Flat 5% off on non- medicine orders above Rs. 700 with OneCard
ONECARD18Flat 18% Off on medicine orders above Rs. 1250 with OneCard
APOLLOMOBIKWIKUpto Rs. 500 cashback on payments above Rs. 999 with Mobikwik Wallet
APLAZYPAYUpto Rs. 300 cashback on 1st transaction of Rs. 500 and above with LazyPay
Secure Payment
Trusted by 8 Crore Indians
Genuine Products
Composition :
GENTAMICIN-80MG
Manufacturer/Marketer :
Marc Laboratories Pvt Ltd
Consume Type :
PARENTERAL
Return Policy :
Not Returnable
Expires on or after :
Drug-Drug Interactions
Severe
Severe
Drug-Drug Interactions
Login/Sign Up
Severe
How does the drug interact with Marcogenta 80 Injection 100 ml:
Co-administration of of clindamycin with Marcogenta 80 Injection 100 ml may increase the risk of kidney and/or nerve damage.
How to manage the interaction:
Although there is a possible interaction, clindamycin can be taken with Marcogenta 80 Injection 100 ml if prescribed by the doctor. Consult the prescriber if you experience signs and symptoms of kidney damage such as sudden weight gain or weight loss, nausea, vomiting, fluid retention, loss of appetite, increased or decreased urination, swelling, shortness of breath, muscle cramps, tiredness, weakness, dizziness, confusion, and irregular heart rhythm. If you develop diarrhea or vomiting during treatment with these medications, drink plenty of fluids to prevent dehydration, as dehydration may also harm the kidney.
Co-administration of of clindamycin with Marcogenta 80 Injection 100 ml may increase the risk of kidney and/or nerve damage.
How to manage the interaction:
Although there is a possible interaction, clindamycin can be taken with Marcogenta 80 Injection 100 ml if prescribed by the doctor. Consult the prescriber if you experience signs and symptoms of kidney damage such as sudden weight gain or weight loss, nausea, vomiting, fluid retention, loss of appetite, increased or decreased urination, swelling, shortness of breath, muscle cramps, tiredness, weakness, dizziness, confusion, and irregular heart rhythm. If you develop diarrhea or vomiting during treatment with these medications, drink plenty of fluids to prevent dehydration, as dehydration may also harm the kidney.
Severe
How does the drug interact with Marcogenta 80 Injection 100 ml:
Taking tacrolimus with Marcogenta 80 Injection 100 ml may cause kidney problems.
How to manage the interaction:
Although there is a possible interaction, Marcogenta 80 Injection 100 ml can be taken with tacrolimus if prescribed by the doctor. However, consult the doctor if you experience symptoms of kidney damage such as nausea, vomiting, loss of hunger, increased or decreased urination, sudden weight gain or weight loss, fluid retention, swelling, shortness of breath, muscle cramps, tiredness, weakness, dizziness, confusion, and irregular heart rhythm. Do not discontinue any medications without consulting a doctor.
Taking tacrolimus with Marcogenta 80 Injection 100 ml may cause kidney problems.
How to manage the interaction:
Although there is a possible interaction, Marcogenta 80 Injection 100 ml can be taken with tacrolimus if prescribed by the doctor. However, consult the doctor if you experience symptoms of kidney damage such as nausea, vomiting, loss of hunger, increased or decreased urination, sudden weight gain or weight loss, fluid retention, swelling, shortness of breath, muscle cramps, tiredness, weakness, dizziness, confusion, and irregular heart rhythm. Do not discontinue any medications without consulting a doctor.
Severe
How does the drug interact with Marcogenta 80 Injection 100 ml:
Co-administration of Vecuronium with Marcogenta 80 Injection 100 ml can make the treatment more effective.
How to manage the interaction:
Taking Vecuronium with Marcogenta 80 Injection 100 ml together can possibly result in an interaction, but it can be taken if a doctor has advised it. If you have any of these symptoms - having trouble breathing or feeling like you can't catch your breath for a long time - it's important to call a doctor right away. Do not stop using any medications without a doctor's advice.
Co-administration of Vecuronium with Marcogenta 80 Injection 100 ml can make the treatment more effective.
How to manage the interaction:
Taking Vecuronium with Marcogenta 80 Injection 100 ml together can possibly result in an interaction, but it can be taken if a doctor has advised it. If you have any of these symptoms - having trouble breathing or feeling like you can't catch your breath for a long time - it's important to call a doctor right away. Do not stop using any medications without a doctor's advice.
How does the drug interact with Marcogenta 80 Injection 100 ml:
Co-administration of Magnesium sulfate with Marcogenta 80 Injection 100 ml can increase the risk of muscle weakness.
How to manage the interaction:
Although there is a possible interaction between Magnesium sulfate and Marcogenta 80 Injection 100 ml, you can take these medicines together if prescribed by a doctor. However, consult a doctor if you experience muscle weakness and breathing difficulties. Do not stop using any medications without talking to a doctor.
Co-administration of Magnesium sulfate with Marcogenta 80 Injection 100 ml can increase the risk of muscle weakness.
How to manage the interaction:
Although there is a possible interaction between Magnesium sulfate and Marcogenta 80 Injection 100 ml, you can take these medicines together if prescribed by a doctor. However, consult a doctor if you experience muscle weakness and breathing difficulties. Do not stop using any medications without talking to a doctor.
How does the drug interact with Marcogenta 80 Injection 100 ml:
Co-administration of Tenofovir alafenamide may cause kidney problems and combining it Marcogenta 80 Injection 100 ml may increase that risk.
How to manage the interaction:
Although there is a possible interaction, Marcogenta 80 Injection 100 ml can be taken with tenofovir alafenamide if prescribed by the doctor. Consult the doctor if you experience signs and symptoms of kidney damage such as nausea, vomiting, loss of appetite, increased or decreased urination, sudden weight gain or weight loss, fluid retention, swelling, shortness of breath, bone pain, muscle cramps, tiredness, weakness, dizziness, confusion, and irregular heart rhythm. Do not stop using any medications without consulting a doctor.
Co-administration of Tenofovir alafenamide may cause kidney problems and combining it Marcogenta 80 Injection 100 ml may increase that risk.
How to manage the interaction:
Although there is a possible interaction, Marcogenta 80 Injection 100 ml can be taken with tenofovir alafenamide if prescribed by the doctor. Consult the doctor if you experience signs and symptoms of kidney damage such as nausea, vomiting, loss of appetite, increased or decreased urination, sudden weight gain or weight loss, fluid retention, swelling, shortness of breath, bone pain, muscle cramps, tiredness, weakness, dizziness, confusion, and irregular heart rhythm. Do not stop using any medications without consulting a doctor.
How does the drug interact with Marcogenta 80 Injection 100 ml:
When Rocuronium is used with Marcogenta 80 Injection 100 ml, it can make the treatment more effective.
How to manage the interaction:
Co-administration of Rocuronium bromide with Marcogenta 80 Injection 100 ml can possibly result in an interaction, but it can be taken if a doctor has advised it. Do not discontinue any medications without consulting a doctor.
When Rocuronium is used with Marcogenta 80 Injection 100 ml, it can make the treatment more effective.
How to manage the interaction:
Co-administration of Rocuronium bromide with Marcogenta 80 Injection 100 ml can possibly result in an interaction, but it can be taken if a doctor has advised it. Do not discontinue any medications without consulting a doctor.
GentamicinFoscarnet
Severe
How does the drug interact with Marcogenta 80 Injection 100 ml:
Co-administration of Marcogenta 80 Injection 100 ml with Foscarnet can increase the risk of kidney damage.
How to manage the interaction:
Although taking Marcogenta 80 Injection 100 ml and Foscarnet together can evidently cause an interaction, it can be taken if a doctor has suggested it. If you have any of these symptoms, it's important to contact your doctor right away: seizures, an irregular heart rhythm, feeling sick, swelling, sudden weight gain or loss, severe pain in your upper stomach, strong heartbeats, feeling dizzy, or chest pain. Do not stop using any medications without a doctor's advice.
Co-administration of Marcogenta 80 Injection 100 ml with Foscarnet can increase the risk of kidney damage.
How to manage the interaction:
Although taking Marcogenta 80 Injection 100 ml and Foscarnet together can evidently cause an interaction, it can be taken if a doctor has suggested it. If you have any of these symptoms, it's important to contact your doctor right away: seizures, an irregular heart rhythm, feeling sick, swelling, sudden weight gain or loss, severe pain in your upper stomach, strong heartbeats, feeling dizzy, or chest pain. Do not stop using any medications without a doctor's advice.
How does the drug interact with Marcogenta 80 Injection 100 ml:
Using Marcogenta 80 Injection 100 ml with Botulinum toxin can increase the risk of side effects.
How to manage the interaction:
Although there is an interaction between Botulinum toxin and Marcogenta 80 Injection 100 ml, they can be taken together if prescribed by a doctor. However, contact a doctor immediately if you experience muscle weakness or trouble breathing, swallowing, or speaking. Do not discontinue any medications without consulting a doctor.
Using Marcogenta 80 Injection 100 ml with Botulinum toxin can increase the risk of side effects.
How to manage the interaction:
Although there is an interaction between Botulinum toxin and Marcogenta 80 Injection 100 ml, they can be taken together if prescribed by a doctor. However, contact a doctor immediately if you experience muscle weakness or trouble breathing, swallowing, or speaking. Do not discontinue any medications without consulting a doctor.
Severe
How does the drug interact with Marcogenta 80 Injection 100 ml:
Co-administration of Marcogenta 80 Injection 100 ml and Temsirolimus may increase the risk of kidney problems.
How to manage the interaction:
Co-administration of Marcogenta 80 Injection 100 ml with Temsirolimus can possibly result in an interaction, but it can be taken if a doctor has advised it. It's important to keep an eye on how much you pee. If you notice any changes like peeing more or less than usual, it's a good idea to let your doctor know right away. Some signs to watch out for include gaining weight quickly, feeling bloated, having trouble breathing, or feeling sick to your stomach. Other symptoms to be aware of are not feeling hungry, losing weight, swelling, muscle cramps, feeling weak or dizzy, feeling confused, or having an irregular heartbeat. Do not stop using any medications without a doctor's advice.
Co-administration of Marcogenta 80 Injection 100 ml and Temsirolimus may increase the risk of kidney problems.
How to manage the interaction:
Co-administration of Marcogenta 80 Injection 100 ml with Temsirolimus can possibly result in an interaction, but it can be taken if a doctor has advised it. It's important to keep an eye on how much you pee. If you notice any changes like peeing more or less than usual, it's a good idea to let your doctor know right away. Some signs to watch out for include gaining weight quickly, feeling bloated, having trouble breathing, or feeling sick to your stomach. Other symptoms to be aware of are not feeling hungry, losing weight, swelling, muscle cramps, feeling weak or dizzy, feeling confused, or having an irregular heartbeat. Do not stop using any medications without a doctor's advice.
How does the drug interact with Marcogenta 80 Injection 100 ml:
Co-administration of Human immunoglobulin with Marcogenta 80 Injection 100 ml may raise the risk of kidney problems.
How to manage the interaction:
Although taking Human immunoglobulin and Marcogenta 80 Injection 100 ml together can cause an interaction, it can be taken if a doctor has suggested it. However, if you experience nausea, vomiting, loss of appetite, increased or decreased urination, sudden weight gain or loss, fluid retention, swelling, shortness of breath, muscle cramps, tiredness, weakness, dizziness, confusion, or an irregular heart rhythm, consult a doctor. Do not discontinue any medications without consulting a doctor.
Co-administration of Human immunoglobulin with Marcogenta 80 Injection 100 ml may raise the risk of kidney problems.
How to manage the interaction:
Although taking Human immunoglobulin and Marcogenta 80 Injection 100 ml together can cause an interaction, it can be taken if a doctor has suggested it. However, if you experience nausea, vomiting, loss of appetite, increased or decreased urination, sudden weight gain or loss, fluid retention, swelling, shortness of breath, muscle cramps, tiredness, weakness, dizziness, confusion, or an irregular heart rhythm, consult a doctor. Do not discontinue any medications without consulting a doctor.
Drug-Food Interactions
No Drug - Food interactions found in our database. Some may be unknown. Consult your doctor for what to avoid during medication.
Drug-Food Interactions
Login/Sign Up
Disclaimer
While we strive to provide complete, accurate, and expert-reviewed content on our 'Platform', we make no warranties or representations and disclaim all responsibility and liability for the completeness, accuracy, or reliability of the aforementioned content. The content on our platform is for informative purposes only, and may not cover all clinical/non-clinical aspects. Reliance on any information and subsequent action or inaction is solely at the user's risk, and we do not assume any responsibility for the same. The content on the Platform should not be considered or used as a substitute for professional and qualified medical advice. Please consult your doctor for any query pertaining to medicines, tests and/or diseases, as we support, and do not replace the doctor-patient relationship.
Author Details
Prescription drugWhats That
coupon
Drug-Diseases Interactions
GENTAMICIN-80MGOther symptoms and signs involving the digestive system and abdomen
Severe
GENTAMICIN-80MGMyasthenia gravis and other myoneural disorders
Severe
Drug-Diseases Interactions
Login/Sign Up
GENTAMICIN-80MGOther symptoms and signs involving the digestive system and abdomen
Severe
How does the disease interact with Marcogenta 80 Injection 100 ml:
Adequate hydration is critical for reducing the risk of oto- and nephrotoxicity associated with aminoglycoside usage. Dehydration should preferably be treated before starting therapy. Fluid status should be continuously maintained in patients who are at risk of dehydration, such as those who have severe and/or prolonged diarrhoea or vomiting. If indications of renal irritation appear during therapy, hydration should be increased as directed, followed by a dose reduction if necessary. If urine flow gradually decreases or azotemia worsens, therapy should be discontinued.
How to manage the interaction:
Dehydration should be corrected prior to initiation of therapy. Fluid status should be monitored closely in patients who may be at risk for dehydration, such as those with severe and/or prolonged diarrhea or vomiting. Therapy should be withdrawn if urinary output decreases progressively or azotemia (elevated levels of urea) increases.
Adequate hydration is critical for reducing the risk of oto- and nephrotoxicity associated with aminoglycoside usage. Dehydration should preferably be treated before starting therapy. Fluid status should be continuously maintained in patients who are at risk of dehydration, such as those who have severe and/or prolonged diarrhoea or vomiting. If indications of renal irritation appear during therapy, hydration should be increased as directed, followed by a dose reduction if necessary. If urine flow gradually decreases or azotemia worsens, therapy should be discontinued.
How to manage the interaction:
Dehydration should be corrected prior to initiation of therapy. Fluid status should be monitored closely in patients who may be at risk for dehydration, such as those with severe and/or prolonged diarrhea or vomiting. Therapy should be withdrawn if urinary output decreases progressively or azotemia (elevated levels of urea) increases.
GENTAMICIN-80MGMyasthenia gravis and other myoneural disorders
Severe
How does the disease interact with Marcogenta 80 Injection 100 ml:
Aminoglycosides can elicit dose-related neuromuscular blockade and muscle weakness, especially in patients with neuromuscular illness or hypocalcemia, as well as in those undergoing general anaesthesia, neuromuscular blocking medications, or substantial transfusions of citrate-anticoagulated blood. Although neuromuscular blockade caused by aminoglycosides is usually self-limiting, it can occasionally result in respiratory paralysis. The most potent neuromuscular blocking drug in the class is regarded to be neomycin. However, the risk is greatest with large dosages instilled intraperitoneally or intrapleurally, or with fast intravenous administration of parenteral aminoglycosides. In patients with neuromuscular problems (e.g., myasthenia gravis, parkinsonian syndrome, botulism) or hypocalcemia, aminoglycoside therapy should be used with caution. If indications of respiratory paralysis appear during aminoglycoside therapy, the medicine should be stopped and, if necessary, mechanical breathing assistance administered.
How to manage the interaction:
Therapy should be administered cautiously in patients with neuromuscular disorders (e.g., myasthenia gravis, Parkinsonian syndrome, botulism) or hypocalcemia (low calcium levels). The drug should be discontinued and mechanical respiratory assistance provided if needed if signs of respiratory paralysis occur during therapy.
Aminoglycosides can elicit dose-related neuromuscular blockade and muscle weakness, especially in patients with neuromuscular illness or hypocalcemia, as well as in those undergoing general anaesthesia, neuromuscular blocking medications, or substantial transfusions of citrate-anticoagulated blood. Although neuromuscular blockade caused by aminoglycosides is usually self-limiting, it can occasionally result in respiratory paralysis. The most potent neuromuscular blocking drug in the class is regarded to be neomycin. However, the risk is greatest with large dosages instilled intraperitoneally or intrapleurally, or with fast intravenous administration of parenteral aminoglycosides. In patients with neuromuscular problems (e.g., myasthenia gravis, parkinsonian syndrome, botulism) or hypocalcemia, aminoglycoside therapy should be used with caution. If indications of respiratory paralysis appear during aminoglycoside therapy, the medicine should be stopped and, if necessary, mechanical breathing assistance administered.
How to manage the interaction:
Therapy should be administered cautiously in patients with neuromuscular disorders (e.g., myasthenia gravis, Parkinsonian syndrome, botulism) or hypocalcemia (low calcium levels). The drug should be discontinued and mechanical respiratory assistance provided if needed if signs of respiratory paralysis occur during therapy.
GENTAMICIN-80MGOther disorders of ear, not elsewhere classified
Severe
How does the disease interact with Marcogenta 80 Injection 100 ml:
Aminoglycosides can harm the eighth cranial nerve, causing vestibular and/or auditory toxicity. Dizziness, nystagmus, vertigo, ataxia, tinnitus, and varied degrees of hearing impairment are among the symptoms. Following the discontinuation of the medicine, permanent hearing loss, including whole or partial irreversible bilateral deafness, may occur. Therapy with aminoglycosides, especially if extended (> 10 days), should be used with caution in patients with preexisting vestibular and/or auditory impairment, as it may delay or obfuscate the diagnosis of a drug-induced ototoxic impact. Patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other ototoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be determined on a regular basis and dosage adjusted to maintain desired levels.
How to manage the interaction:
Therapy should be administered with caution in patients with ototoxicity. The dosage should be reduced or therapy shoule be withdrawn if signs and symptoms of toxicity develop.
Aminoglycosides can harm the eighth cranial nerve, causing vestibular and/or auditory toxicity. Dizziness, nystagmus, vertigo, ataxia, tinnitus, and varied degrees of hearing impairment are among the symptoms. Following the discontinuation of the medicine, permanent hearing loss, including whole or partial irreversible bilateral deafness, may occur. Therapy with aminoglycosides, especially if extended (> 10 days), should be used with caution in patients with preexisting vestibular and/or auditory impairment, as it may delay or obfuscate the diagnosis of a drug-induced ototoxic impact. Patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other ototoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be determined on a regular basis and dosage adjusted to maintain desired levels.
How to manage the interaction:
Therapy should be administered with caution in patients with ototoxicity. The dosage should be reduced or therapy shoule be withdrawn if signs and symptoms of toxicity develop.
GENTAMICIN-80MGUnspecified kidney failure
Severe
How does the disease interact with Marcogenta 80 Injection 100 ml:
Aminoglycosides have the potential to be ototoxic and nephrotoxic. Damage to the eighth cranial nerve can cause vestibular and/or auditory toxicities such as dizziness, nystagmus, vertigo, ataxia, tinnitus, and varied degrees of hearing impairment. Tubular necrosis, increases in BUN, nonprotein nitrogen, and serum creatinine concentration, decreases in urine specific gravity and creatinine clearance, proteinuria, and cells or casts in the urine are all signs of nephrotoxicity. Rarely, renal electrolyte wasting can cause hypocalcemia, hypomagnesemia, and hypokalemia, which can be accompanied with paresthesia, tetany, disorientation, and positive Chvostek and Trousseau symptoms. Although aminoglycoside-induced nephrotoxicity is often reversible after treatment withdrawal, mortality from uremia has happened on rare occasions. Patients with renal impairment should be treated with caution and at lower doses of aminoglycosides, as they may be at risk.Drug buildup increases the risk of oto- and nephrotoxicity. Patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be determined on a regular basis and dosage adjusted to maintain desired levels. If toxicity develops, renal and eighth cranial nerve function should be constantly monitored, and the dosage lowered or therapy discontinued.
How to manage the interaction:
Therapy should be administered cautiously at reduced dosages in patients with kidney impairment. Patients should be adequately hydrated, the dose should not be exceeded, and use with other neuro- and nephrotoxic agents should be avoided to minimize the risk of toxicity.
Aminoglycosides have the potential to be ototoxic and nephrotoxic. Damage to the eighth cranial nerve can cause vestibular and/or auditory toxicities such as dizziness, nystagmus, vertigo, ataxia, tinnitus, and varied degrees of hearing impairment. Tubular necrosis, increases in BUN, nonprotein nitrogen, and serum creatinine concentration, decreases in urine specific gravity and creatinine clearance, proteinuria, and cells or casts in the urine are all signs of nephrotoxicity. Rarely, renal electrolyte wasting can cause hypocalcemia, hypomagnesemia, and hypokalemia, which can be accompanied with paresthesia, tetany, disorientation, and positive Chvostek and Trousseau symptoms. Although aminoglycoside-induced nephrotoxicity is often reversible after treatment withdrawal, mortality from uremia has happened on rare occasions. Patients with renal impairment should be treated with caution and at lower doses of aminoglycosides, as they may be at risk.Drug buildup increases the risk of oto- and nephrotoxicity. Patients should be adequately hydrated, the usual aminoglycoside dosage should not be exceeded, use with other neuro- and nephrotoxic agents should be avoided, and peak and trough serum aminoglycoside concentrations should be determined on a regular basis and dosage adjusted to maintain desired levels. If toxicity develops, renal and eighth cranial nerve function should be constantly monitored, and the dosage lowered or therapy discontinued.
How to manage the interaction:
Therapy should be administered cautiously at reduced dosages in patients with kidney impairment. Patients should be adequately hydrated, the dose should not be exceeded, and use with other neuro- and nephrotoxic agents should be avoided to minimize the risk of toxicity.
Have a query?
